Phacilitate Leaders Forum

Phacilitate Leaders Europe Agenda 2018

Loading

Part 2: What does the ideal centre of excellence look like for ATMPs?

11-Sep-2018
Shared workshops
  • What are the substantial barriers to adoption of these therapies in the clinical setting?
  • Training: What does clinician training look like and how can manufacturers help?
  • What qualifications do clinicians need to have to be able to work with these specialised treatments?
  • What is the optimal staffing set up in hospitals/academic centres to ensure the maximum number of patients are treated?
  • Delivery of care for CAR-T’s in Europe. Are 2-3 centres of excellence in one country enough? How does this work with the current infrastructure?
Speakers
Diego Ardigo, Head R&D Rare Diseases Unit Head - Chiesi Farmaceutici SpA
Marc Turner, Medical Director - Scottish National Blood Transfusion Service
Michela Gabaldo, Head, Alliance Management & Regulatory Affairs - San Raffaele-Telethon Institute for Gene Therapy
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
    Celyad
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd